Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment

Main Article Content

Jan Turner, Pandora Pound, Carla Owen, Isobel Hutchinson, Marina Hop, David Y. S. Chau, Lady V. Barrios Silva, Mike Coleman, Audrey Dubourg, Lorna W. Harries, Victoria Hutter, J. Gerry Kenna, Volker M. Lauschke, Winfried Neuhaus, Clive Roper, Paul B. Watkins, Jonathan Welch, Laura Rego Alvarez , Katy Taylor
[show affiliations]


New approach methodologies (NAMs) based on human biology enable the assessment of adverse biological effects of pharmaceuticals and other chemicals. Currently, however, it is unclear how NAMs should be used during drug development to improve human safety evaluation. A series of 5 workshops with 13 international experts (regulators, preclinical scientists, and NAMs developers) was conducted to identify feasible NAMs and to discuss how to exploit them in specific safety assessment contexts. Participants generated four “maps” of how NAMs can be exploited in the safety assessment of the liver, respiratory, cardiovascular, and central nervous systems. Each map shows relevant endpoints measured and tools used (e.g., cells, assays, platforms), and highlights gaps where further development and validation of NAMs remains necessary. Each map addresses the fundamental scientific requirements for the safety assessment of that organ system, providing users with guidance on the selection of appropriate NAMs. In addition to generating the maps, participants offered suggestions for encouraging greater NAM adoption within drug development and their inclusion in regulatory guidelines. A specific recommendation was that pharmaceutical companies should be more transparent about how they use NAMs in-house. As well as giving guidance for the four organ systems, the maps provide a template that could be used for additional organ safety testing contexts. Moreover, their conversion to an interactive format would enable users to drill down to the detail necessary to answer specific scientific and regulatory questions.

Article Details

How to Cite
Turner, J. (2023) “Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment”, ALTEX - Alternatives to animal experimentation, 40(3), pp. 519–533. doi: 10.14573/altex.2212081.
Meeting Reports

Andersen, M., McMullen, P., Phillips, M. et al. (2019). Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). ALTEX 36, 523-534. doi:10.14573/altex.1906261

Avila, A. M., Bebenek, I., Bonzo, J. A. et al. (2020). An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol 114, 104662. doi:10.1016/j.yrtph.2020.104662

Bai, J. P. F., Earp, J. C., Strauss, D. G. et al. (2020). A perspective on quantitative systems pharmacology applications to clinical drug development. CPT Pharmacometrics Syst Pharmacol 9, 675-677. doi:10.1002/psp4.12567

Bailey, J., Thew, M. and Balls, M. (2015). Predicting human drug toxicity and safety via animal tests: Can any one species predict drug toxicity in any other, and do monkeys help? Altern Lab Anim 43, 393-403. doi:10.1177/026119291504300607

Balogh Sivars, K., Sivars, U., Hornberg, E. et al. (2018). A 3D human airway model enables prediction of respiratory toxicity of inhaled drugs in vitro. Toxicol Sci 162, 301-308. doi:10.1093/toxsci/kfx255

Bartfeld, S. and Clevers, H. (2017). Stem cell-derived organoids and their application for medical research and patient treatment. J Mol Biol 95, 729-738. doi:10.1007/s00109-017-1531-7

Baudy, A. R., Otieno, M. A., Hewitt, P. et al. (2020). Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip 20, 215-225. doi:10.1039/C9LC00768G

Bowes, J., Brown, A. J., Hamon, J. et al. (2012). Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nat Rev Drug Discov 11, 909-922. doi:10.1038/nrd3845

Bracher, M., Pilkington, G. J., Hanemann, C. O. et al. (2020). A systematic approach to review of in vitro methods in brain tumour research (SAToRI-BTR): Development of a preliminary checklist for evaluating quality and human relevance. Front Bioeng Biotechnol 8, 1-17. doi:10.3389/fbioe.2020.00936

Burgdorf, T., Piersma, A. H., Landsiedel, R. et al. (2019). Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology – Evolution versus revolution. Toxicol In Vitro 9, 1-11. doi:10.1016/j.tiv.2019.03.039

Busquet, F., Hartung, T., Pallocca, G. et al. (2020). Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines. Arch Toxicol 94, 2263-2272. doi:10.1007/s00204-020-02787-2

Butler, L. D., Guzzie-Peck, P., Hartke, J. et al. (2017). Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective. Regul Toxicol Pharmacol 87, Suppl 3, S1-S15. doi:10.1016/j.yrtph.2017.05.009

Chioccioli, M., Feriani, L., Kotar, J. et al. (2019). Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in cystic fibrosis respiratory epithelial cells. Nat Commun 10, 1763. doi:10.1038/s41467-019-09798-3

Choudhury, Y., Toh, Y. C., Xing, J. et al. (2017). Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep 7, 41238. doi:10.1038/srep41238

Clippinger, A. J., Allen, D., Jarabek, A. M. et al. (2018). Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicol In Vitro 48, 53-70. doi:10.1016/j.tiv.2017.12.011

Cook, D., Brown, D., Alexander, R. et al. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework. Nat Rev Drug Discov 13, 419-431. doi:10.1038/nrd4309

Corley, R. A., Kuprat, A. P., Suffield, S. R. et al. (2021). New approach methodology for assessing inhalation risks of a contact respiratory cytotoxicant: Computational fluid dynamics-based aerosol dosimetry modeling for cross-species and in vitro comparisons. Toxicol Sci 182, 243-259. doi:10.1093/toxsci/kfab062

Dirven, H., Vist, G. E., Bandhakavi, S. et al. (2021). Performance of preclinical models in predicting drug-induced liver injury in humans: A systematic review. Sci Rep 11, 6403. doi:10.1038/s41598-021-85708-2

EMA – European Medicines Agency (2018). Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation.

EMA (2021). Mandate, Objectives and Rules of Procedure of the Scientific Advice Working Party (SAWP).

Ewart, L., Apostolou, A., Briggs, S. A. et al. (2022). Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med 2, 154. doi:10.1038/s43856-022-00209-1

Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H. et al. (2021). Advanced preclinical models for evaluation of drug-induced liver injury – Consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET]. J Hepatol 75, 935-959. doi:10.1016/j.jhep.2021.06.021

Ferrari, E. and Rasponi, M. (2021). Liver-heart on chip models for drug safety. APL Bioeng 5, 031505. doi:10.1063/5.0048986

Fontana, R. J. (2008). Acute liver failure due to drugs. Semin Liver Dis 28, 175-187. doi:10.1055/s-2008-107311747

Fowler, S., Chen, W. L. K., Duignan, D. B. et al. (2020). Microphysiological systems for ADME-related applications: Current status and recommendations for system development and characterization. Lab Chip 20, 446-467. doi:10.1039/C9LC00857H

Franzen, N., van Harten, W. H., Retèl, V. P. et al. (2019). Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov Today 24, 1720-1724. doi:10.1016/j.drudis.2019.06.003

Gocke, E., Müller, L., Guzzie, P. J. et al. (2000). Considerations on photochemical genotoxicity: Report of the international workshop on genotoxicity test procedures working group. Environ Mol Metagen 35, 173-184. doi:10.1002/(sici)1098-2280(2000)35:3<173::aid-em4>;2-e

Guo, Y. and Pu, W. T. (2020). Cardiomyocyte maturation. Circ Res 126, 1086-1106. doi:10.1161/circresaha.119.315862

Hardy, A., Benford, D., Halldorsson, T. et al. (2017). Update: Use of the benchmark dose approach in risk assessment. EFSA J 15, e04658. doi:10.2903/j.efsa.2017.4658

Hill, E. J., Jiménez-González, C., Tarczyluk, M. et al. (2012). NT2 derived neuronal and astrocytic network signalling. PLoS One 7, e36098. doi:10.1371/journal.pone.0036098

ICCVAM – Interagency Coordinating Committee on the Validation of Alternative Methods. (2018). A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States.

ICH – International Conference on Harmonisation (2000). Guideline S7A Safety Pharmacology Studies for Human Pharmaceuticals.

ICH (2009). Guideline M3(R2) on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals Step 5.

ICH (2018). Final Concept Paper on ICH S7B and E14 Q&A; 15 November.

IPCS and IOMC – International Programme on Chemical Safety and Inter-Organization Programme for the Sound Management of Chemicals (‎2010)‎. Characterization and application of physiologically based pharmacokinetic models in risk assessment. World Health Organization.

Kanda, Y., Yamazaki, D., Osada, T. et al. (2018). Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS cardiac safety assessment (JiCSA) update. J Pharmacol Sci 138, 233-239. doi:10.1016/j.jphs.2018.10.010

Kennedy, R., Kuvshinov, D., Sdrolia, A. et al. (2019). A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens. Sci Rep 9, 6327. doi:10.1038/s41598-019-42745-2

Kuprat, A. P., Jalali, M., Jan, T. et al. (2021). Efficient bi-directional coupling of 3D computational fluid-particle dynamics and 1D multiple path particle dosimetry lung models for multiscale modeling of aerosol dosimetry. J Aerosol Sci 151, 105647. doi:10.1016/j.jaerosci.2020.105647

LASA and NC3Rs (2009). Guidance on Dose Level Selection for Regulatory General Toxicology Studies for Pharmaceuticals.

Lauschke, V. M., Vorrink, S. U., Moro, S. M. L. et al. (2016a). Massive rearrangements of cellular microRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology 64, 1743-1756. doi:10.1002/hep.28780

Lauschke, V. M., Hendriks, D. F. G., Bell, C. C. et al. (2016b). Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem Res Toxicol 29, 1936-1955. doi:10.1021/acs.chemrestox.6b00150

Lauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G. et al. (2019). 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: Emerging culture paradigms and applications. Biotechnol J 14, 1800347. doi:10.1002/biot.201800347

Lemme, M., Ulmer, B. M., Lemoine, M. D. et al. (2018). Atrial-like engineered heart tissue: An in vitro model of the human atrium. Stem Cell Rep 11, 1378-1390. doi:10.1016/j.stemcr.2018.10.008

Li, W., Luo, X., Ulbricht, Y. et al. (2019). Establishment of an automated patch-clamp platform for electrophysiological and pharmacological evaluation of hiPSC-CMs. Stem Cell Rep 41, 101662. doi:10.1016/j.scr.2019.101662

Lin, C. and Khetani, S. R. (2016). Advances in engineered liver models for investigating drug-induced liver injury. Biomed Res Int 2016, 1829148. doi:10.1155/2016/1829148

Liu, L., Yu, L., Li, Z. et al. (2021). Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med 19, 40. doi:10.1186/s12967-020-02677-2

Morgan, P., Brown, D. G., Lennard, S. et al. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 17, 167-181. doi:10.1038/nrd.2017.244

Nantasanti, S., de Bruin, A., Rothuizen, J. et al. (2016). Concise review: Organoids are a powerful tool for the study of liver disease and personalized treatment design in humans and animals. Stem Cells Transl Med 5, 325-330. doi:10.5966/sctm.2015-0152

NASEM – National Academies of Sciences, Engineering, and Medicine (2021). Microphysiological Systems: Bridging Human and Animal Research – A Workshop.

Ouchi, R., Togo, S., Kimura, M. et al. (2019). Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab 30, 374-384.e6. doi:10.1016/j.cmet.2019.05.007

Pamies, D., Leist, M., Coecke, S. et al. (2022). Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). ALTEX 39, 30-70. doi:10.14573/altex.2111011

Parish, S. T., Aschner, M., Casey, W. et al. (2020). An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regul Toxicol Pharmacol 112, 104592. doi:10.1016/j.yrtph.2020.104592

Patterson, E. A., Whelan, M. P. and Worth, A. P. (2021). The role of validation in establishing the scientific credibility of predictive toxicology approaches intended for regulatory application. Comput Toxicol 17, 100144. doi:10.1016/j.comtox.2020.100144

Peterson, N. C., Mahalingaiah, P. K., Fullerton, A. et al. (2020). Application of microphysiological systems in biopharmaceutical research and development. Lab Chip 20, 697-708. doi:10.1039/C9LC00962K

Piersma, A. H., Burgdorf, T., Louekari, K. et al. (2018). Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. Toxicol In Vitro 50, 62-74. doi:10.1016/j.tiv.2018.02.018

Pointon, A., Harmer, A. R., Dale, I. L. et al. (2015). Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 144, 227-237. doi:10.1093/toxsci/kfu312

Pointon, A., Maher, J., Davis, M. et al. (2021). Cardiovascular microphysiological systems (CVMPS) for safety studies – A pharma perspective. Lab Chip 21, 458-472. doi:10.1039/D0LC01040E

Primavessy, D., Metz, J., Schnur, S. et al. (2021). Pulmonary in vitro instruments for the replacement of animal experiments. Eur J Pharm Biopharm 168, 62-75. doi:10.1016/j.ejpb.2021.08.005

Rubiano, A., Indapurkar, A., Yokosawa, R. et al. (2021). Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci 14, 1049-1061. doi:10.1111/cts.12969

Sadler, R. C., Prime, D., Burnell, P. K. et al. (2011). Integrated in vitro experimental modelling of inhaled drug delivery: Deposition, dissolution and absorption. J Drug Deliv Sci Technol 21, 331-338. doi:10.1016/S1773-2247(11)50051-6

Smith, B., Rowe, J., Watkins, P. B. et al. (2020). Mechanistic investigations support liver safety of ubrogepant. Toxicol Sci 177, 84-93. doi:10.1093/toxsci/kfaa093

Su, F. S., Lee, C. F., Rajendran, P. et al. (2020). Nasal airflow simulation on healthy child using computational fluid dynamics. Technol Reports Kansai Univ 62.

Takayama, K., Morisaki, Y., Kuno, S. et al. (2014). Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc Natl Acad Sci 111, 16772-16777. doi:10.1073/pnas.1413481111

Thomas, D., Chancellor, D., Micklus, A. et al. (2021). Clinical Development Success Rates and Contributing Factors 2011-2020.

Tsega, E. G. (2018). Computational fluid dynamics modeling of respiratory airflow in tracheobronchial airways of infant, child, and adult. Comput Math Methods Med 2018, 9603451. doi:10.1155/2018/9603451

US EPA – US Environmental Protection Agency (2016). Benchmark Dose Software (BMDS). User Manual.

US FDA – US Food and Drug Administration (2017). Predictive Toxicology Roadmap. & research/published/FDA%27s-Predictive-Toxicology-Roadmap.pdf

US FDA (2018). Physiologically Based Pharmacokinetic Analyses – Format and Content. Guidance for Industry.

US FDA (2019). Liver Toxicity Knowledge Base (LTKB).

US FDA (2021a). Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.

US FDA (2021b). Advancing New Alternative Methodologies (NAMs) at FDA.

US FDA (2021c). Advancing Alternative Methods at FDA.

Varewyck, M. and Verbeke, T. (2017). Software for benchmark dose modelling. EFSA Support Publ 14, 1170E. doi:10.2903/sp.efsa.2017.EN-1170

Wang, X., Wang, L., Dou, W. et al. (2020). Electrical impedance-based contractile stress measurement of human iPSC-Cardiomyocytes. Biosens Bioelectron 166, 112399. doi:10.1016/j.bios.2020.112399

Ware, B. R., Berger, D. R. and Khetani, S. R. (2015). Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 145, 252-262. doi:10.1093/toxsci/kfv048

Watkins, P. B. (2011). Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 89, 788-790. doi:10.1038/clpt.2011.63

Watkins, P. B. (2020). DILIsym: Quantitative systems toxicology impacting drug development. Curr Opin Toxicol 23-24, 67-73. doi:10.1016/j.cotox.2020.06.003

Woehrling, E. K., Parri, H. R., Tse, E. H. Y. et al. (2015). A predictive in vitro model of the impact of drugs with anticholinergic properties on human neuronal and astrocytic systems. PLoS One 10, e0118786. doi:10.1371/journal.pone.0118786

Woodhead, J. L., Brock, W. J., Roth, S. E. et al. (2017). Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci 155, 61-74. doi:10.1093/toxsci/kfw193

Yin, S., Xi, R., Wu, A. et al. (2020). Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci Transl Med 12, eaaz1723. doi:10.1126/scitranslmed.aaz1723

Zhang, X., Jiang, T., Chen, D. et al. (2020). Three-dimensional liver models: State of the art and their application for hepatotoxicity evaluation. Crit Rev Toxicol 50, 279-309. doi:10.1080/10408444.2020.1756219

Most read articles by the same author(s)

1 2 > >>